Anti-angiogenic alternatives to VEGF blockade

Clinical and Experimental Metastasis

Volumn 33, Issue 2, 2016, Pages 197-210

  Khan, Kabir A ^a   Bicknell, Roy ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Angiogenesis; Anti angiogenesis; Cancer; Therapy; Tumour

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; CD146 ANTIGEN; CLEC14A PROTEIN; ENDOGLIN; EPHRIN; EPHRIN RECEPTOR; FIBROBLAST GROWTH FACTOR; INTEGRIN; LIGAND; NOTCH RECEPTOR; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; ANTINEOPLASTIC AGENT; VASCULOTROPIN A;

ANGIOGENESIS; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84958747810     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-015-9769-3     Document Type: Review

References (135)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70
2. Kim KJ, Li B, Houck K, Winer J, Ferrara N (1992) The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7(1):53–64
3. Vasudev NS, Reynolds AR (2014) Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17(3):471–494
4. Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8(4):299–309
5. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3):232–239
6. Paez-Ribes M, Allen E, Hudock J et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3):220–231
7. Lee S, Chen TT, Barber CL et al (2007) Autocrine VEGF signaling is required for vascular homeostasis. Cell 130(4):691–703
8. Luo J, Xiong Y, Han X, Lu Y (2011) VEGF non-angiogenic functions in adult organ homeostasis: therapeutic implications. J Mol Med (Berl) 89(7):635–645
9. Gacche RN, Meshram RJ (2013) Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth. Prog Biophys Mol Biol 113(2):333–354
10. Javerzat S, Auguste P, Bikfalvi A (2002) The role of fibroblast growth factors in vascular development. Trends Mol Med 8(10):483–489
11. Kopetz S, Hoff PM, Morris JS et al (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28(3):453–459
12. Compagni A, Wilgenbus P, Impagnatiello MA, Cotten M, Christofori G (2000) Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 60(24):7163–7169
13. Li D, Wei X, Xie K, Chen K, Li J, Fang J (2014) A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth. Br J Cancer 111(1):68–77
14. Wang L, Park H, Chhim S et al (2012) A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. Mol Cancer Ther 11(4):864–872
15. Camozzi M, Rusnati M, Bugatti A et al (2006) Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem 281(32):22605–22613
16. Ronca R, Alessi P, Coltrini D et al (2013) Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer. J Pathol 230(2):228–238
17. Ronca R, Giacomini A, Di SE et al (2015) Long-pentraxin 3 derivative as a small-molecule FGF trap for cancer therapy. Cancer Cell 28(2):225–239
18. Bashkin P, Doctrow S, Klagsbrun M, Svahn CM, Folkman J, Vlodavsky I (1989) Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28(4):1737–1743
19. Aigner A, Butscheid M, Kunkel P et al (2001) An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer 92(4):510–517
20. Schulze D, Plohmann P, Hobel S, Aigner A (2011) Anti-tumor effects of fibroblast growth factor-binding protein (FGF-BP) knockdown in colon carcinoma. Mol Cancer 10:144
21. Zhang Q, Lao X, Huang J et al (2014) Soluble production and function of vascular endothelial growth factor/basic fibroblast growth factor complex peptide. Biotechnol Prog
22. Heldin CH, Eriksson U, Ostman A (2002) New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys 398(2):284–290
23. Enge M, Bjarnegard M, Gerhardt H et al (2002) Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J 21(16):4307–4316
24. Sennino B, Falcon BL, McCauley D et al (2007) Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 67(15):7358–7367
25. Lu C, Shahzad MM, Moreno-Smith M et al (2010) Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 9(3):176–182
26. Dewerchin M, Carmeliet P (2012) PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med 2(8)
27. Fischer C, Jonckx B, Mazzone M et al (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131(3):463–475
28. Brave SR, Eberlein C, Shibuya M, Wedge SR, Barry ST (2010) Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model. Angiogenesis 13(4):337–347
29. Bais C, Wu X, Yao J et al (2010) PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 141(1):166–177
30. Augustin HG, Koh GY, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10(3):165–177
31. Bogdanovic E, Nguyen VP, Dumont DJ (2006) Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor internalization. J Cell Sci 119(Pt 17):3551–3560
32. Yuan HT, Khankin EV, Karumanchi SA, Parikh SM (2009) Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 29(8):2011–2022
33. Thurston G, Rudge JS, Ioffe E et al (2000) Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6(4):460–463
34. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG (2005) The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 118(Pt 4):771–780
35. Felcht M, Luck R, Schering A et al (2012) Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest 122(6):1991–2005
36. Maisonpierre PC, Suri C, Jones PF et al (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277(5322):55–60
37. Tait CR, Jones PF (2004) Angiopoietins in tumours: the angiogenic switch. J Pathol 204(1):1–10
38. Oliner J, Min H, Leal J et al (2004) Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6(5):507–516
39. Monk BJ, Poveda A, Vergote I et al (2014) Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15(8):799–808
40. Brindle NP, Sale JE, Arakawa H et al (2013) Directed evolution of an angiopoietin-2 ligand trap by somatic hypermutation and cell surface display. J Biol Chem 288(46):33205–33212
41. Leow CC, Coffman K, Inigo I et al (2012) MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int J Oncol 40(5):1321–1330
42. Daly C, Eichten A, Castanaro C et al (2013) Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 73(1):108–118
43. Kienast Y, Klein C, Scheuer W et al (2013) Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res 19(24):6730–6740
44. Rigamonti N, Kadioglu E, Keklikoglou I, Wyser RC, Leow CC, De PM (2014) Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep 8(3):696–706
45. Kuhnert F, Kirshner JR, Thurston G (2011) Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vasc Cell 3(1):20
46. Iso T, Hamamori Y, Kedes L (2003) Notch signaling in vascular development. Arterioscler Thromb Vasc Biol 23(4):543–553
47. Limbourg FP, Takeshita K, Radtke F, Bronson RT, Chin MT, Liao JK (2005) Essential role of endothelial Notch1 in angiogenesis. Circulation 111(14):1826–1832
48. Williams CK, Li JL, Murga M, Harris AL, Tosato G (2006) Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107(3):931–939
49. Hellstrom M, Phng LK, Hofmann JJ et al (2007) Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445(7129):776–780
50. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D (2001) Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 69(2–3):135–144
51. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL (2005) Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 65(19):8690–8697
52. Ridgway J, Zhang G, Wu Y et al (2006) Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444(7122):1083–1087
53. Noguera-Troise I, Daly C, Papadopoulos NJ et al (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444(7122):1032–1037
54. Scehnet JS, Jiang W, Kumar SR et al (2007) Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 109(11):4753–4760
55. Thurston G, Noguera-Troise I, Yancopoulos GD (2007) The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer 7(5):327–331
56. Wu Y, Cain-Hom C, Choy L et al (2010) Therapeutic antibody targeting of individual Notch receptors. Nature 464(7291):1052–1057
57. Funahashi Y, Hernandez SL, Das I et al (2008) A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res 68(12):4727–4735
58. Kangsamaksin T, Murtomaki A, Kofler NM et al (2014) Notch decoys that selectively block Dll/Notch or Jagged/Notch disrupt angiogenesis by unique mechanisms to inhibit tumor growth. Cancer Discov 2014
59. Yan M, Callahan CA, Beyer JC et al (2010) Chronic DLL4 blockade induces vascular neoplasms. Nature 463(7282):E6–E7
60. Liu Z, Turkoz A, Jackson EN et al (2011) Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J Clin Investig 121(2):800–808
61. Erdreich-Epstein A, Shimada H, Groshen S et al (2000) Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res 60(3):712–721
62. Carlson TR, Hu H, Braren R, Kim YH, Wang RA (2008) Cell-autonomous requirement for beta1 integrin in endothelial cell adhesion, migration and survival during angiogenesis in mice. Development 135(12):2193–2202
63. Weis SM, Cheresh DA (2011) alphaV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med 1(1):a006478
64. Pierschbacher MD, Ruoslahti E (1984) Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309(5963):30–33
65. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA (1995) Definition of two angiogenic pathways by distinct alpha v integrins. Science 270(5241):1500–1502
66. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264(5158):569–571
67. Vonlaufen A, Wiedle G, Borisch B, Birrer S, Luder P, Imhof BA (2001) Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. Mod Pathol 14(11):1126–1132
68. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Investig 96(4):1815–1822
69. Gutheil JC, Campbell TN, Pierce PR et al (2000) Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6(8):3056–3061
70. Hersey P, Sosman J, O’Day S et al (2010) A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or—dacarbazine in patients with stage IV metastatic melanoma. Cancer 116(6):1526–1534
71. Dechantsreiter MA, Planker E, Matha B et al (1999) N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 42(16):3033–3040
72. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL (2002) Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62(15):4263–4272
73. Stupp R, Hegi ME, Gorlia T et al (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1100–1108
74. Reynolds AR, Hart IR, Watson AR et al (2009) Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med 15(4):392–400
75. Wong PP, Demircioglu F, Ghazaly E et al (2015) Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell 27(1):123–137
76. Ramakrishnan V, Bhaskar V, Law DA et al (2006) Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 5(4):273–286
77. Bhaskar V, Zhang D, Fox M et al (2007) A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med 5:61
78. Besse B, Tsao LC, Chao DT et al (2013) Phase Ib safety and pharmacokinetic study of volociximab, an anti-alpha5beta1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 24(1):90–96
79. Dejana E, Bazzoni G, Lampugnani MG (1999) Vascular endothelial (VE)-cadherin: only an intercellular glue? Exp Cell Res 252(1):13–19
80. Prandini MH, Dreher I, Bouillot S, Benkerri S, Moll T, Huber P (2005) The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis. Oncogene 24(18):2992–3001
81. Corada M, Zanetta L, Orsenigo F et al (2002) A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 100(3):905–911
82. May C, Doody JF, Abdullah R et al (2005) Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature. Blood 105(11):4337–4344
83. Li H, Shi X, Liu J et al (2010) The soluble fragment of VE-cadherin inhibits angiogenesis by reducing endothelial cell proliferation and tube capillary formation. Cancer Gene Ther 17(10):700–707
84. Kullander K, Klein R (2002) Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3(7):475–486
85. Holland SJ, Gale NW, Mbamalu G, Yancopoulos GD, Henkemeyer M, Pawson T (1996) Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands. Nature 383(6602):722–725
86. Mosch B, Reissenweber B, Neuber C, Pietzsch J (2010) Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis. J Oncol 2010:135285
87. McBride JL, Ruiz JC (1998) Ephrin-A1 is expressed at sites of vascular development in the mouse. Mech Dev 77(2):201–204
88. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB (2000) The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19(52):6043–6052
89. Cheng N, Brantley DM, Liu H et al (2002) Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 1(1):2–11
90. Brantley DM, Cheng N, Thompson EJ et al (2002) Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21(46):7011–7026
91. Dobrzanski P, Hunter K, Jones-Bolin S et al (2004) Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 64(3):910–919
92. Wang HU, Chen ZF, Anderson DJ (1998) Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93(5):741–753
93. Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB (2004) Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci USA 101(15):5583–5588
94. Sawamiphak S, Seidel S, Essmann CL et al (2010) Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465(7297):487–491
95. Djokovic D, Trindade A, Gigante J et al (2010) Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer 10:641
96. Li X, Choi WW, Yan R et al (2014) The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder. PLoS ONE 9(8):e105326
97. Mura M, Swain RK, Zhuang X et al (2012) Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene 31(3):293–305
98. Noy PJ, Lodhia P, Khan K et al (2015) Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth. Oncogene
99. Zanivan S, Maione F, Hein MY et al (2013) SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers. Mol Cell Proteomics 12(12):3599–3611
100. Rho SS, Choi HJ, Min JK et al (2011) Clec14a is specifically expressed in endothelial cells and mediates cell to cell adhesion. Biochem Biophys Res Commun 404(1):103–108
101. Ki MK, Jeoung MH, Choi JR et al (2013) Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro. Oncogene 32(48):5449–5457
102. St CB, Rago C, Velculescu V et al (2000) Genes expressed in human tumor endothelium. Science 289(5482):1197–1202
103. Nanda A, Carson-Walter EB, Seaman S et al (2004) TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res 64(3):817–820
104. Cullen M, Seaman S, Chaudhary A et al (2009) Host-derived tumor endothelial marker 8 promotes the growth of melanoma. Cancer Res 69(15):6021–6026
105. Chaudhary A, Hilton MB, Seaman S et al (2012) TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell 21(2):212–226
106. Duan HF, Hu XW, Chen JL et al (2007) Antitumor activities of TEM8-Fc: an engineered antibody-like molecule targeting tumor endothelial marker 8. J Natl Cancer Inst 99(20):1551–1555
107. Wang Z, Yan X (2013) CD146, a multi-functional molecule beyond adhesion. Cancer Lett 330(2):150–162
108. Zeng Q, Wu Z, Duan H et al (2014) Impaired tumor angiogenesis and VEGF-induced pathway in endothelial CD146 knockout mice. Protein Cell 5(6):445–456
109. Flanagan K, Fitzgerald K, Baker J et al (2012) Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS. PLoS ONE 7(7):e40443
110. Tu T, Zhang C, Yan H et al (2015) CD146 acts as a novel receptor for netrin-1 in promoting angiogenesis and vascular development. Cell Res 25(3):275–287
111. Jiang T, Zhuang J, Duan H et al (2012) CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 120(11):2330–2339
112. Cheifetz S, Bellon T, Cales C et al (1992) Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267(27):19027–19030
113. Rokhlin OW, Cohen MB, Kubagawa H, Letarte M, Cooper MD (1995) Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J Immunol 154(9):4456–4465
114. Li DY, Sorensen LK, Brooke BS et al (1999) Defective angiogenesis in mice lacking endoglin. Science 284(5419):1534–1537
115. Burrows FJ, Derbyshire EJ, Tazzari PL et al (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1(12):1623–1634
116. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C (2002) Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 277(46):43799–43808
117. Bockhorn M, Tsuzuki Y, Xu L, Frilling A, Broelsch CE, Fukumura D (2003) Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin Cancer Res 9(11):4221–4226
118. Takahashi N, Haba A, Matsuno F, Seon BK (2001) Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 61(21):7846–7854
119. Tsujie M, Tsujie T, Toi H et al (2008) Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int J Cancer 122(10):2266–2273
120. Nolan-Stevaux O, Zhong W, Culp S et al (2012) Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies. PLoS ONE 7(12):e50920
121. Liu Y, Tian H, Blobe GC, Theuer CP, Hurwitz HI, Nixon AB (2014) Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. Investig New Drugs 32(5):851–859
122. Gordon MS, Robert F, Matei D et al (2014) An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res 20(23):5918–5926
123. Ruckman J, Green LS, Beeson J et al (1998) 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273(32):20556–20567
124. LaFleur DW, Abramyan D, Kanakaraj P et al (2013) Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides. MAbs 5(2):208–218
125. Wentink MQ, Huijbers EJ, de Gruijl TD, Verheul HM, Olsson AK, Griffioen AW (2015) Vaccination approach to anti-angiogenic treatment of cancer. Biochim Biophys Acta 1855(2):155–171
126. Carbonell WS, Ansorge O, Sibson N, Muschel R (2009) The vascular basement membrane as “soil” in brain metastasis. PLoS ONE 4(6):e5857
127. Valiente M, Obenauf AC, Jin X et al (2014) Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156(5):1002–1016
128. Moschetta M, Mishima Y, Sahin I et al (2014) Role of endothelial progenitor cells in cancer progression. Biochim Biophys Acta 1846(1):26–39
129. Kerbel RS, Guerin E, Francia G et al (2013) Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. Breast 22(Suppl 2):S57–S65
130. Gerber HP, Wu X, Yu L et al (2007) Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci USA 104(9):3478–3483
131. Toi H, Tsujie M, Haruta Y, Fujita K, Duzen J, Seon BK (2015) Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105). Int J Cancer 136(2):452–461
132. Wang H, Yang H, Shivalila CS et al (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153(4):910–918
133. Zhuang X, Herbert JM, Lodhia P et al (2015) Identification of novel vascular targets in lung cancer. Br J Cancer 112(3):485–494
134. van Beijnum JR, Dings RP, van der Linden E et al (2006) Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 108(7):2339–2348
135. Pepin F, Bertos N, Laferriere J et al (2012) Gene-expression profiling of microdissected breast cancer microvasculature identifies distinct tumor vascular subtypes. Breast Cancer Res 14(4):R120